- Cabaletta Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
- Cabaletta Bio Announces FDA Granted Orphan Drug Designation to CABA-201 for Treatment of Systemic Sclerosis
- Cabaletta Bio to Participate in Upcoming Investor Conferences in March
- Cabaletta Bio Announces FDA Granted Orphan Drug Designation to CABA-201 for Treatment of Myositis
- Cabaletta Bio to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
- Cabaletta Bio Receives Additional FDA Fast Track Designations for CABA-201 in Dermatomyositis and Systemic Sclerosis
- Cabaletta Bio to Present at the 42nd Annual J.P. Morgan Healthcare Conference
- Cabaletta Bio to Participate in the 6th Annual Evercore ISI HealthCONx Conference
- Cabaletta Bio Reports Third Quarter 2023 Financial Results and Provides Business Update
- Cabaletta Bio Receives FDA Clearance of CABA-201 IND Application for Treatment of Generalized Myasthenia Gravis
More ▼
Key statistics
As of last trade, Cabaletta Bio Inc (CABA:NSQ) traded at 12.07, 56.96% above the 52 week low of 7.69 set on Apr 25, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 12.47 |
---|---|
High | 12.68 |
Low | 11.77 |
Bid | 12.01 |
Offer | 12.24 |
Previous close | 12.96 |
Average volume | 978.91k |
---|---|
Shares outstanding | 46.80m |
Free float | 43.29m |
P/E (TTM) | -- |
Market cap | 606.59m USD |
EPS (TTM) | -1.65 USD |
Data delayed at least 15 minutes, as of Apr 25 2024 14:43 BST.
More ▼